Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 23, 2020

Imperial College London gets UK funding for Covid-19 vaccine

Imperial College London has secured £22.5m from the UK Government to accelerate the development of a potential Covid-19 vaccine.

Imperial College London has secured £22.5m from the UK Government to accelerate the development of a potential Covid-19 vaccine.

Since February, researchers at Imperial have been studying a self-amplifying RNA vaccine candidate in animals.

Upon administration, the vaccine will deliver genetic instructions to muscle cells generating the ‘spike’ protein found on the coronavirus’ surface. This mechanism is expected to trigger an immune response and create immunity against Covid-19.

Early findings from animals studies showed that the vaccine led to the generation of neutralising antibodies against SARS-CoV-2, the novel coronavirus that causes Covid-19.

The Imperial team is currently developing the vaccine further, with plans for human clinical trials.

The government funding will be used to support Phase II trials and to make preparations for a large Phase III trial.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Meanwhile, researchers are looking for additional philanthropic support for parallel international trials to expedite development and allow global availability, including in low and middle-income countries.

Imperial College London Department of Infectious Disease professor Robin Shattock said: “This investment will help us accelerate our clinical programme, moving from starting human safety trials in June through to testing whether the vaccine can prevent infection in the wider community.

“We are working as fast as we can to determine the vaccine’s efficacy and to get to a position where millions or billions of the vaccine can be manufactured rapidly.”

In addition, Imperial has also joined a trial led by the University of Oxford, which is developing the ChAdOx1 nCoV-19 vaccine candidate against the novel coronavirus.

The university also secured £20m in funding from the UK Government to support the vaccine trial that will be performed over six months at multiple centres across the country.

Imperial College NHS Trust is currently enrolling healthy participants for the study.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU